Analysis of Early Outcomes of Pencil Beam Proton Therapy Compared with Passive Scattering Proton Therapy for Clival Chordoma.


Journal

World neurosurgery
ISSN: 1878-8769
Titre abrégé: World Neurosurg
Pays: United States
ID NLM: 101528275

Informations de publication

Date de publication:
Mar 2023
Historique:
received: 12 09 2022
revised: 15 12 2022
accepted: 15 12 2022
pubmed: 24 12 2022
medline: 8 3 2023
entrez: 23 12 2022
Statut: ppublish

Résumé

To assess the early outcomes of the following 2 types of proton therapy: passive scattering proton therapy (PSPT) and pencil beam proton therapy (PBPT). The consecutive patients who had surgery in our facility were retrospectively reviewed. Thirty-two patients were identified (PBPT 22 patients [69%]). The mean (±standard deviation [SD]) tumor size was 3.8 ± 1.8 cm, and the most common location was the upper clivus (41%). Four cases (13%) were revision surgeries referred from elsewhere, and 2 cases underwent additional surgery elsewhere to achieve near-total resection before radiation. The cerebrospinal fluid leak occurred in 3 patients (9%). The mean (±SD) prescribed dose of PSPT and PBPT was 74 ± 3 Gy and 72 ± 3 Gy, respectively (P = 0.07). The mean (±SD) fractionation of PSPT and PBPT was 39 ± 2 and 36 ± 2, respectively (P = 0.001). Radiation toxicities were recorded in endocrine (11 patients [34%]), ophthalmic (3 patients [9%]), otologic (7 patients [22%]), and radiation necrosis (4 patients [13%]). PSPT was associated with endocrinopathy (odds ratio [OR], 10.5; 95% confidence interval, 1.86-59.4, P = 0.008), and radiation dose was associated with otologic toxicity (OR 1.57; 95% confidence interval, 1.02-2.44; P = 0.04). The gross-near total resection group had better progression-free survival than the subtotal resection group regardless of radiation therapy (P = 0.01). Overall, 3-year progression-free survival was 73%, and 5-year overall survival was 93%. The PBPT group showed comparable outcome to the PSPT group. The degree of resection was more important than the modality of proton therapy. Further follow-up and cases are necessary to evaluate the benefit of PBPT.

Identifiants

pubmed: 36563848
pii: S1878-8750(22)01785-5
doi: 10.1016/j.wneu.2022.12.081
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e644-e653

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Sukwoo Hong (S)

Department of Neurological Surgery, Mayo Clinic, Rochester, Minnesota, USA.

Nadia Laack (N)

Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.

Anita Mahajan (A)

Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.

Garret Choby (G)

Department of Otolaryngology, Mayo Clinic, Rochester, Minnesota, USA.

Erin O'Brien (E)

Department of Otolaryngology, Mayo Clinic, Rochester, Minnesota, USA.

Janalee Stokken (J)

Department of Otolaryngology, Mayo Clinic, Rochester, Minnesota, USA.

Jeffrey Janus (J)

Department of Otolaryngology, Mayo Clinic, Rochester, Minnesota, USA.

Jamie J Van Gompel (JJ)

Department of Neurological Surgery, Mayo Clinic, Rochester, Minnesota, USA; Department of Otolaryngology, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: vangompel.jamie@mayo.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH